Single-cell spatial mapping of human hippocampus in early alzheimer's disease
Active Grant Awarded
- Award ID
- FAG106806UPRRG7
- Recipient
-
Mayo Clinic UEI Y2K4F9RPRRG7 Part of Mayo Clinic
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $50,314
Award facts
- Assistance listing
- 93.AG4 National Institute on Aging Training Individual Projects
- Completion date 1% complete
- Place of performance
- Rochester, MN 55905, USA
Award details come from USAspending.gov.
Description
- Abstract
- Alzheimer's disease (ad) presents an enormous and growing burden on individuals, caregivers, and communities as our population continues to age. To date, we lack effective therapies to prevent or halt ad. Aging is the single greatest risk factor for mild cognitive impairment (MCI) due to ad, and this condition may represent a critical early window for interventions that slow or stop disease progression. The hippocampus and its white matter output tracts undergo significant structural and functional changes in both brain aging and MCI due to ad, but the cellular interactions that occur within neuropathological niches remain incompletely characterized. The objective of this research is to investigate how senescence, a cellular stress response that occurs in the aging brain, may contribute to these alterations observed in ad. Senescent microglia exhibiting a disease associated microglia (DAM) phenotype have been shown to accumulate within brain tissue in mouse models of aging. The accumulation of senescent glia and neurons has also been demonstrated in human ad and ad mouse models. The convergence of senescent phenotypes observed across aging and ad suggests that senescence may link physiological age-related stress response to maladaptive early-stage neuroinflammation and neuropathology. We hypothesize that senescent microglia accumulate in human hippocampal white matter regions in the context of prodromal alzheimer's disease and exhibit distinct transcriptomic and proteomic signatures predictive of pro-inflammatory microenvironment remodeling. We will use advanced single-cell spatial mapping approaches to accomplish our objectives. These techniques offer a significant advantage over conventional methods by allowing for the visualization and high-dimensional molecular phenotyping of senescent cells within their native tissue architecture. We will first apply high-plex, single-cell transcriptomic mapping to hippocampal tissue from older adults with diagnosis of MCI due to ad and cognitively unimpaired (CU) controls. These analyses will define the spatial distribution, transcriptomic signatures, and cell-cell interaction networks of senescent cell populations that are associated with ad neuropathology. Using serial sections of the same human samples, we will perform spatially resolved proteomic profiling of senescent cell populations with laser capture microdissection-guided mass spectrometry. We will characterize which molecular pathways are represented in these proteomic signatures and assess how they correlate with our transcriptomic findings. Together, these studies will establish a spatially resolved molecular atlas of the human hippocampus during prodromal ad. By defining how senescent cell populations shape and respond to the tissue microenvironment during early phases of disease, this work will provide insight into how a physiological aging mechanism contributes to ad and may identify new targets for therapeutic intervention.
Quick answers
Who received award FAG106806UPRRG7?
FAG106806UPRRG7 was awarded to Mayo Clinic by National Institute on Aging (National Institutes of Health) on November 16, 2026.
How much is award FAG106806UPRRG7 worth?
$50,314 has been obligated on FAG106806UPRRG7.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award